Gilead Sciences (GILD) News Today $109.33 +0.42 (+0.39%) Closing price 04:00 PM EasternExtended Trading$109.29 -0.04 (-0.04%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GILD Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCOJune 3 at 3:34 PM | cnbc.comAEGON ASSET MANAGEMENT UK Plc Increases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)AEGON ASSET MANAGEMENT UK Plc raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 285,817 shares of the biopharmaceutical comJune 3 at 7:18 AM | marketbeat.comCGN Advisors LLC Decreases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)CGN Advisors LLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 15.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 26,171 shares of the biopharmaceutical company's stock afterJune 3 at 6:54 AM | marketbeat.comUnigestion Holding SA Buys New Stake in Gilead Sciences, Inc. (NASDAQ:GILD)Unigestion Holding SA bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 38,596 shares of the biopharmaceutical company's stock, valued at approxJune 3 at 6:53 AM | marketbeat.comFulton Bank N.A. Sells 3,622 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Fulton Bank N.A. decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 10.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,415 shares of the biopharmaceutical company's stock after sellingJune 3 at 5:50 AM | marketbeat.comBaker Tilly Wealth Management LLC Sells 3,273 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Baker Tilly Wealth Management LLC decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 58.7% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,300 shares of the biopharmaceutical company's stock after seJune 3 at 5:01 AM | marketbeat.comInsider Selling: Gilead Sciences, Inc. (NASDAQ:GILD) CEO Sells 10,000 Shares of StockJune 3 at 4:22 AM | insidertrades.comCiti Analysts Affirm Buy Rating on Gilead Sciences (GILD) StockJune 2 at 9:39 PM | msn.comWright Investors Service Inc. Has $5.68 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Wright Investors Service Inc. raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 50,665 shares of the biopharmaceutical company's stock afteJune 2 at 7:54 AM | marketbeat.comMilestone Asset Management LLC Increases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)Milestone Asset Management LLC increased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 170.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 60,343 shares of the biopharmaceutical company's stock after pJune 2 at 7:53 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Czech National BankCzech National Bank boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 286,312 shares of the biopharmaceutical company'sJune 2 at 7:36 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Position Decreased by Rhumbline AdvisersRhumbline Advisers decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,255,140 shares of the biopharmaceuJune 2 at 6:26 AM | marketbeat.comWorth Asset Management LLC Buys 5,626 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Worth Asset Management LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 62.8% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 14,589 shares of the biopharmaceutical company's stock after buying an additional 5,626 sharesJune 2 at 6:18 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Investors Research CorpInvestors Research Corp lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 96.4% in the first quarter, according to its most recent filing with the SEC. The firm owned 415 shares of the biopharmaceutical company's stock after selling 11,121 shares during the quaJune 2 at 5:53 AM | marketbeat.comDouglas Lane & Associates LLC Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)Douglas Lane & Associates LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 2,479 shares of the biopharmaceutical company's stock, valued atJune 2 at 5:51 AM | marketbeat.comMechanics Bank Trust Department Grows Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Mechanics Bank Trust Department grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 51.8% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 10,260 shares of the biopharmaceutical company's stock after bJune 2 at 5:32 AM | marketbeat.comGilead Sciences Inc (GILD) Announces Promising Real-World Data for Yescarta in Outpatient ...June 1 at 9:05 AM | gurufocus.comVeery Capital LLC Acquires New Position in Gilead Sciences, Inc. (NASDAQ:GILD)Veery Capital LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 2,501 shares of the biopharmaceutical company's stock, valued atJune 1 at 8:16 AM | marketbeat.com2,432 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by J2 Capital Management IncJ2 Capital Management Inc purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 2,432 shares of the biopharmaceutical coJune 1 at 8:07 AM | marketbeat.comGilead's CAR-T cell therapy shows promise in deadly brain cancerJune 1 at 8:03 AM | reuters.comKite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025June 1 at 8:00 AM | businesswire.comMeyer Handelman Co. Cuts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Meyer Handelman Co. lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 365,524 shares of the biopharmaceuticJune 1 at 7:58 AM | marketbeat.comLantz Financial LLC Lowers Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Lantz Financial LLC reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 13.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 22,233 shares of the biopharmaceutical company's stock after selling 3,367 sJune 1 at 6:47 AM | marketbeat.comBTC Capital Management Inc. Lowers Stake in Gilead Sciences, Inc. (NASDAQ:GILD)BTC Capital Management Inc. lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 11.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 47,330 shares of the biopharmaceuticaJune 1 at 6:47 AM | marketbeat.comParallel Advisors LLC Has $3.83 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)Parallel Advisors LLC reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 7.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,164 shares of the biopharmaceutical company'June 1 at 6:17 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by GAMMA Investing LLCGAMMA Investing LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 13,891.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,550,298 shares of the biopharmaceutical companJune 1 at 6:07 AM | marketbeat.comGilead Sciences, Inc, (GILD)’s Trodelvy and Merck & Co., Inc, (MRK)’s Keytruda Cuts Breast Cancer Progression Risk by 35%May 31 at 8:48 PM | insidermonkey.comGilead Sciences Inc (GILD) Announces Promising Results for Trodelvy and Keytruda Combination in ...May 31 at 7:12 PM | gurufocus.comGilead Sciences (GILD) Reports Positive Results for Trodelvy Combo in Breast Cancer StudyMay 31 at 7:12 PM | gurufocus.comGilead’s Trodelvy plus Merck’s Keytruda cuts disease progression/ death in breast cancerMay 31 at 9:46 AM | msn.comGilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trialMay 31 at 8:13 AM | reuters.comTrodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast CancerMay 31 at 8:00 AM | businesswire.comSummit Global Investments Cuts Position in Gilead Sciences, Inc. (NASDAQ:GILD)Summit Global Investments decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 31.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 35,070 shares of the biopharMay 31 at 6:55 AM | marketbeat.comFarmers Trust Co. Has $5.46 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)Farmers Trust Co. decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 23.3% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 48,734 shares of the biopharmaceutical company's stock after selling 14,793 shares duMay 31 at 6:01 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Wealth Enhancement Advisory Services LLCWealth Enhancement Advisory Services LLC lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 13.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 279,772 shares of the biopharmaceutical company's stockMay 31 at 5:06 AM | marketbeat.comGilead Eyes HIV Drug Rollout In Low-Income Countries Despite Funding Uncertainty, Says Report: Retail Holds Onto Bearish StanceMay 30, 2025 | msn.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Boston Common Asset Management LLCBoston Common Asset Management LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 14.8% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 133,128 shares of the biopharmaceutical company's stock after purchasing an additMay 30, 2025 | marketbeat.comConfluence Investment Management LLC Has $109.81 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)Confluence Investment Management LLC decreased its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 16.7% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 979,976 shares of the biopharmaceutical company's stock afteMay 30, 2025 | marketbeat.comFirst Financial Bank Trust Division Has $7.20 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)First Financial Bank Trust Division decreased its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 13.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,213 shares of theMay 30, 2025 | marketbeat.comFocus: Gilead commits to HIV prevention rollout for low-income countries despite funding uncertaintyMay 30, 2025 | reuters.comPKO Investment Management Joint Stock Co Invests $554,000 in Gilead Sciences, Inc. (NASDAQ:GILD)PKO Investment Management Joint Stock Co purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 6,000 sharesMay 30, 2025 | marketbeat.comGilead Sciences, Inc. (GILD) Bernstein 41st Annual Strategic Decisions Conference (Transcript)May 29, 2025 | seekingalpha.com111 Capital Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)111 Capital purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 10,776 shares of the biopharmaceutical company's stock, valued at aMay 29, 2025 | marketbeat.comAnchor Pointe Wealth Management LLC Invests $245,000 in Gilead Sciences, Inc. (NASDAQ:GILD)Anchor Pointe Wealth Management LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 2,667 shares of the biopharmaceuMay 29, 2025 | marketbeat.comB. Riley Wealth Advisors Inc. Sells 8,087 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)B. Riley Wealth Advisors Inc. lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 40.4% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 11,919 shares of the biopharmaceutical company's stock after selling 8,087 shares duMay 29, 2025 | marketbeat.comTalaria Asset Management Pty Ltd Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)Talaria Asset Management Pty Ltd bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 147,700 shares of the biopharmaceutical company's stock, valued at approximatelMay 28, 2025 | marketbeat.comFluent Financial LLC Takes $2.69 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)Fluent Financial LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 29,156 shares of the biopharmaceutical coMay 28, 2025 | marketbeat.comBridgePort Financial Solutions LLC Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)BridgePort Financial Solutions LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,866 shares of the biopharmaceuMay 28, 2025 | marketbeat.comTotal Wealth Planning & Management Inc. Invests $496,000 in Gilead Sciences, Inc. (NASDAQ:GILD)Total Wealth Planning & Management Inc. purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 5,374 shares of the biopharmMay 28, 2025 | marketbeat.com1,130,256 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Universal Beteiligungs und Servicegesellschaft mbHUniversal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 1,130,256 shares of the biopharmaceutical company's stock,May 28, 2025 | marketbeat.com Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address GILD Media Mentions By Week GILD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GILD News Sentiment▼1.310.88▲Average Medical News Sentiment GILD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GILD Articles This Week▼5531▲GILD Articles Average Week Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AMGN News Today VRTX News Today REGN News Today ALNY News Today BIIB News Today UTHR News Today INCY News Today NBIX News Today EXEL News Today BMRN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GILD) was last updated on 6/3/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gilead Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gilead Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
